Blood cancers

New options for older patients with AML

Newer hypomethylating agents like azacitidine offer hope for older patients with acute myeloid leukaemia, according to Professor Hervé Dombret from the University Hospital Saint-Louis in Paris. “The current approach subdivides older patients into those capable of tolerating intensive chemotherapy, those who may only tolerate low-intensity therapy such as low-dose cytarabine or hypomethylating agents like azacitidine, ...

Already a member?

Login to keep reading.

© 2021 the limbic